In recent years, intravitreal injection of anti-VEGF drugs for the treatment of ROP, with advantages of simple operation, minimal invasion, and continuous growing of retinal vessels to the periphery after injection, has gradually become an important treatment method [7–9]. This evidence concerns the gene VEGFA and retinopathy of prematurity.